" class="no-js "lang="en-US"> Vial Announces the Addition of Dr. Marc Hoffmann from the University of Kansas Medical Center to their Oncology CRO Scientific Advisory Board - Medtech Alert
Friday, April 12, 2024

Vial Announces the Addition of Dr. Marc Hoffmann from the University of Kansas Medical Center to their Oncology CRO Scientific Advisory Board

Vial, a tech-enabled CRO providing next-generation clinical trial management services, announced the addition of Marc Hoffmann, MD, to Vial’s Scientific Advisory Board. Dr. Hoffmann will work closely with the company’s leadership team to shape the scientific strategy of Vial’s Oncology CRO products and services.

“Vial’s vision is to empower scientists to cure all human disease. We are elated to see our vision endorsed by such an esteemed leader in oncology. Undoubtedly, Dr. Hoffmann will be an invaluable resource as we advance our Oncology CRO and technology platform,” said Richard McCormick Jr., VP of Oncology at Vial.

Vial promises to deliver faster, more efficient trials for biotech sponsors at up to 50% less cost. The Vial Oncology CRO distinguishes itself by leveraging digital technology, such as its Vial Technology Platform, combining eSource, EDC, eTMF, and ePRO into one connected system to streamline site processes. These best-in-class CRO services will accelerate the development of new therapies and devices for oncology sponsors and patients.

“I am excited to provide guidance to the Vial team as they progress their Oncology CRO and technology platform. Vial is committed to empowering oncology research teams to discover new therapies for patients with cancer through more efficient clinical trial processes. I am eager to see their progress as they continue their product development,” said Marc Hoffmann.

Dr. Hoffman is the Medical Director for Lean and Quality Improvement in the Cancer Center, Chair of the Lymphoma/Myeloma Disease Working Group, and an associate professor at the University of Kansas.

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more